Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer. The selective oral CDK4/6 ...

C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 positive, staying vigilant in looking for signs of adverse events (AEs) is ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...